All In Biotech

NDA 200732 · Pharmobedient

Zidovudine

Zidovudine · Oral

Discontinued

Last checked: Nov 19, 2026Latest source record: Dec 27, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Feb 23, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

497

105 Phase 3, 3 recruiting

FAERS reports

10,367

9,840 serious, 1,459 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 23, 2011 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • ZIDOVUDINE · ZIDOVUDINE 100MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Zidovudine" as an intervention, any sponsor and status, largest first.

All 497 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy1,625
  • virologic failure778
  • drug resistance709
  • anaemia617
  • exposure during pregnancy588
  • pathogen resistance585
  • drug exposure during pregnancy580
  • viral mutation identified567
  • premature baby497
  • maternal exposure during pregnancy428
  • treatment failure420
  • lipodystrophy acquired413

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004342
2005319
2006479
2007447
2008445
2009480
2010459
2011347
2012282
2013298
2014344
2015534
20161,064
2017902
2018740
2019607
2020706
2021405
2022359
2023357
2024174
2025136
2026139

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zidovudine (Zidovudine)

2024 spending

$169K

Beneficiaries

398

2,642 claims

Per beneficiary

$424

$0.73 per unit

View as table
YearSpending
2020$298,564
2021$239,429
2022$235,499
2023$211,258
2024$168,652

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,520 on PubMed

Sponsor: Pharmobedient

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.